A notable advancement in diabetes care is emerging with the introduction of tirzepatide at a dosage of 45mg. This innovative offering builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://socialmediatotal.com/story6420575/revolutionary-approach-tirzepatide-45mg-for-glucose-management